Alira Health Welcomes Olga Carroll, Ph.D as Vice President, Regulatory

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced that Olga Carroll, Ph.D. joined the firm as Vice President of Regulatory. Olga brings an extensive background and notable experience in regulatory affairs and is based out of Alira Health’s Framingham, Massachusetts headquarters.
Olga joins Alira Health with over 20 years of global experience in pharma, biotech, and the medical device industry including the United States, Europe, and Asia-Pacific. Her background includes broad and in-depth strategic and implementation experience in the end-to-end development and commercialization of small and large molecules, biologics, biosimilars, and combination products in Therapeutic Areas of high unmet medical need. Her primary focus is on oncology, hematology, neurology, and orphan, rare, and ultra-rare adult, and pediatric disease.

“We are thrilled to welcome Olga to the Alira Health family. Olga’s extensive background and experience will add significant expertise and depth to our growing Regulatory affairs practice,” said Giacomo Basadonna, Chief Medical Officer at Alira Health. “Olga’s addition to the team will also be invaluable in boosting our global capabilities in MedTech and Pharma regulatory strategy.”

“I am excited to join Alira Health’s fast-growing advisory organization offering state-of-the-art services to the US, Europe, and global small, medium, and large pharma and biotech clients. I look forward to helping to advance our clients’ promising pre-clinical and clinical-stage platforms in numerous therapeutic areas of high unmet medical need,” said Olga. “I am honored to work with this great team of people who have such tremendous and diverse cross-functional subject matter expertise. It is exciting to be a part of such a dynamic organization striving for excellence, growth, and success serving patients, their families, and the medical community.”

Olga’s expertise extends to global regulatory clinical strategy and competitive intelligence, commercialization of gene/cell therapies, collecting real-world evidence to ensure reimbursement for approved medicinal products, pre-clinical strategy, and cross-functional project management.
Olga’s previous experience includes extensive regulatory, competitive, and due diligence assessments, GAP, and SWAT analyses in CMC, clinical, medical, and regulatory strategy, and global regulatory leadership. She has worked with clients around the globe, including Bayer, Pfizer, Mallinckrodt Pharma, Biogen, Sanofi-Genzyme, Boston Biomedical.

To learn more about the Alira Health team, please visit https://www.alirahealth.com/about-us/team/.